TY - JOUR
T1 - Sulphidoleukotriene release of cord blood basophils in response to allergen stimulation correlates with neither a family history of atopy nor a subsequent development of atopic eczema
AU - Walaschek, C.
AU - Heinzmann, A.
AU - Weckmann, M.
AU - Kopp, M. V.
N1 - Copyright:
Copyright 2009 Elsevier B.V., All rights reserved.
PY - 2008/3
Y1 - 2008/3
N2 - Objective: We tested a possible relationship between sulphidoleukotriene (SLT) release of cord blood (CB) basophils, a family history of atopy (HA) and subsequent development of atopic eczema. Population and methods: A cohort of 86 neonates were involved (48.8% males; 46.5% with a positive HA+). CB samples were analysed for in vitro SLT release quantified by ELISA, and in a subgroup for basophilic activation (CD 63 expression) by flow cytometry in response to a positive control (anti-IgE-receptor antibody), an allergen-mix (TOP and PTOP), egg white (EW), egg yolk (EY), and the purified allergens β-lactoglobulin (BLG) and α-lactalbumin (ALA). Results: Median concentrations of SLT were 124.2 (negative), 3871.5 (positive), 123.9 (TOP), 128.5 (PTOP), 113.1 (EW), 108.4 (EY), 125.2 (BLG) and 122.3 (ALA) pg/mL. Groups of HA+ and HA- show no difference in all analysed allergens. An allergen-specific SLT release (defined as SLT>125 pg/mL above individual baseline and a stimulation index >2) was detected in 98% (positive control), 5% (TOP), 7% (BLG), 3% (ALA) and 2% (EW and EY), respectively. After a median observation period of 18 months, n=7 out of 70 children developed an atopic eczema, but we observed no association between CB SLT release (positive response to at least one tested allergen). Conclusion: Allergen-specific SLT release is detectable in 15.5% of healthy neonates, irrespective of their family history of atopy. However, early allergen-specific SLT release is not predictive for the development of atopy.
AB - Objective: We tested a possible relationship between sulphidoleukotriene (SLT) release of cord blood (CB) basophils, a family history of atopy (HA) and subsequent development of atopic eczema. Population and methods: A cohort of 86 neonates were involved (48.8% males; 46.5% with a positive HA+). CB samples were analysed for in vitro SLT release quantified by ELISA, and in a subgroup for basophilic activation (CD 63 expression) by flow cytometry in response to a positive control (anti-IgE-receptor antibody), an allergen-mix (TOP and PTOP), egg white (EW), egg yolk (EY), and the purified allergens β-lactoglobulin (BLG) and α-lactalbumin (ALA). Results: Median concentrations of SLT were 124.2 (negative), 3871.5 (positive), 123.9 (TOP), 128.5 (PTOP), 113.1 (EW), 108.4 (EY), 125.2 (BLG) and 122.3 (ALA) pg/mL. Groups of HA+ and HA- show no difference in all analysed allergens. An allergen-specific SLT release (defined as SLT>125 pg/mL above individual baseline and a stimulation index >2) was detected in 98% (positive control), 5% (TOP), 7% (BLG), 3% (ALA) and 2% (EW and EY), respectively. After a median observation period of 18 months, n=7 out of 70 children developed an atopic eczema, but we observed no association between CB SLT release (positive response to at least one tested allergen). Conclusion: Allergen-specific SLT release is detectable in 15.5% of healthy neonates, irrespective of their family history of atopy. However, early allergen-specific SLT release is not predictive for the development of atopy.
UR - http://www.scopus.com/inward/record.url?scp=38849140835&partnerID=8YFLogxK
U2 - 10.1111/j.1365-2222.2007.02923.x
DO - 10.1111/j.1365-2222.2007.02923.x
M3 - Journal articles
C2 - 18269669
AN - SCOPUS:38849140835
SN - 0954-7894
VL - 38
SP - 458
EP - 465
JO - Clinical and Experimental Allergy
JF - Clinical and Experimental Allergy
IS - 3
ER -